Business Wire

Owl Labs Launches Meeting Owl ® 4+ Camera and AI-Powered Software to Create the First Standalone 360-Degree, Wirelessly Connected Device System for Hybrid Work

Share

Owl Labs, the first company to build AI-powered, 360-degree video conferencing solutions, today launched its next-generation flagship product, the Meeting Owl 4+. It is Owl Labs’ newest all-in-one, 360-degree camera, speaker, and mic device with 4K Ultra HD video for crystal clear video that’s sharper than ever. The new Meeting Owl is powered by the latest Owl Intelligence System (OIS) Software which now allows for wirelessly pairing more devices, so organisations can customise their spaces to meet their evolving needs.

Over 200,000 organisations across nearly 50 countries, from small businesses to 89 companies on the Fortune 100 list to educational institutions, have used Owl Labs products to power millions of hybrid experiences. Owl devices use robotics and proprietary, patented AI-powered software to automatically switch between cameras to capture the best view of in-room attendees, enabling natural, face-to-face conversations that transcend physical distance. With the introduction of the Meeting Owl 4+, Owl Labs now offers enhanced capabilities to more audiences, from small and medium-sized businesses (SMBs) to larger enterprises. In addition to pairing with more devices to cover larger spaces, the Meeting Owl 4+ has several other enterprise-friendly features, including easier fleet management for IT teams and customisable lighting and sound options upon startup.

With the latest AI-powered OIS software, the Meeting Owl 4+ pairs with Owl Labs’ customisable connected device system to capture all angles of the discussion. Owl Labs products can connect with others in over 25 different setup configurations, with both centre-of-room and front-and-centre options. For example, a company can wirelessly connect two Meeting Owls for greater coverage, or a Meeting Owl and an Owl BarTM to ensure all angles are covered, creating a full-room solution. The software is developed in the U.S. by an experienced team of engineers who are continually iterating to make Owl products smarter over time. All software adheres to industry-standard security protocols and Owl devices connect via a private, dedicated wireless network.

This launch is the latest advancement in Owl Labs’ mission to make hybrid meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. Hundreds of thousands of workplaces have moved beyond traditional conference room setups with equipment permanently mounted to walls and transitioned to user-friendly, plug-and-play Owl products with the flexibility, portability, and affordability that modern distributed offices need. Any type of meeting, in any size room, is covered with Owl Labs’ tailored technology, from sit-down roundtables to stand-up presentations to brainstorms on whiteboards. As companies grow, their video conferencing infrastructure adapts and expands with them. However, a vast market opportunity remains as Owl Labs’ State of Hybrid Work report found only 37% of employers upgraded their video meeting technology in the past year.

“Non-verbal communication is crucial in the workplace for collaboration and rapport, and studies have even shown that non-verbal communication is at least as important as verbal discussion, if not more,” said Frank Weishaupt, CEO of Owl Labs. “As the hybrid workplace has evolved beyond meetings where everyone is in the same room, we need to do away with outdated video technology that doesn't allow remote attendees to clearly see and hear during meetings. Meanwhile, today’s enterprise businesses are evolving their offices and processes faster than ever to keep up with the pace of economic and AI-driven transformation. At Owl Labs, we’re building easy-to-use meeting technology that’s as nimble as they are, from small businesses to the largest enterprises.”

The flexible, plug-and-play Meeting Owl 4+ is enterprise-ready and takes less than six minutes to set up. Features include:

  • Upgraded video quality: The 64-megapixel camera and sensor streams 4K Ultra HD video within a 10-foot radius.
  • Wide-range audio: Powerful,360-degree speakers and smart mics have an 18-foot pickup radius. Extend the audio range even farther with the new matching, charcoal Expansion Mic.
  • Easy enterprise fleet management: IT administrators can seamlessly manage their fleet of Owl Labs devices from The Nest management tool, including bulk registration, default settings, and more.

The upgraded OIS software includes:

  • Silent Switching: When devices are paired, the technology detects where people are facing even when they’re not speaking, then seamlessly switches to the correct camera with the best view.
  • Quick and easy setup: Pair devices quickly, effortlessly and efficiently.
  • Platform-agnostic: Compatible with Microsoft Teams, Zoom, Google Meet, Slack, and other video conferencing platforms.
  • Improved Front + Centre Experience: Front + Centre experience upgrades introduce more accurate intelligent camera switching whether a participant is actively speaking or silently contributing to ensure the best angle is captured at all times.

The new Meeting Owl 4+ is launching in the United States, Canada and Europe. Customers in the UK can now purchase it for £1,999 / €2,199 (including VAT) through OwlLabs.com, Amazon, or third-party resellers and distribution partners. Find your local reseller or contact sales@owllabs.com.

To see video of the Meeting Owl 4+ in action, purchase other Owl Labs products or ensure your devices have the latest OIS software, visit owllabs.co.uk.

About Owl Labs:

Owl Labs is the first company to build AI-powered, 360-degree video conferencing solutions for hybrid organisations. Its connected device system and Owl Intelligence System™ software make meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. The Meeting Owl® 4+ is the latest generation of the first WiFi-enabled, 360-degree camera, microphone and speaker that automatically zooms in on whoever’s speaking. Owl Labs has raised £36.8 million in funding and is based in Boston, with remote and hybrid employees all over the world. To learn more and explore the company’s research on the State of Hybrid Work, visit OwlLabs.co.uk.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

sales@owllabs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye